Creating new life forms that may help eradicate cancer affecting women

February 26, 2007

Instead of using the usual cancer-fighting modalities, surgery, chemotherapy, or radiation, researchers from a drug development company called Advaxis, have embarked on a novel approach to fighting cancer: Engaging the immune system to attack cancer in the same the way it would a flu vaccine, by creating new life forms.

Dr. Vafa Shahabi, Advaxis' Director of Research and Development, reports that because the human immune system is not designed to fight cancer on its own, she and her colleagues are trying to harness its power through a new kind of life form: specifically a family of vaccines, which they call Lovaxin. The vaccines are comprised of new strains of bacteria created in Advaxis' laboratory that are programmed to kill off specific cancers.

The Key: A Microbe Found in Dairy Products

Central to this startling discovery is the microbe Listeria monocytogenes, a common bacterium found in milk, cheese and other dairy products. This microorganism apparently aids in fighting cancer by activating the body's own killer (cytotoxic T) cells to elicit a stronger than normal immune response to the presence of cancer cells. The vaccines "teach" the immune system to mount a specialized, targeted response that is lethal to cancer.

When Listeria is introduced in the body, it has a powerful, direct stimulatory effect on the activities of tumor-killing T cells. "Essentially the modified Listeria vaccines harness the power of the immune system against this infectious agent," explains Dr. Shabahi, "and then directs it to successfully attack cancer cells. The bacterium in effect then becomes a cancer-fighting 'Trojan horse,' with the enemy tucked inside."

For breast cancer, Dr. Shababi's team fused Listeria with a tumor-associated protein, HER-2/Neu, to immune cells, to create a vaccine called Lovaxin B. What these cells do is enlist killer T cells to seek and destroy tumor cells that over-express the HER-2/Neu molecule. This is significant because HER-2/Neu is over- expressed in 20%- 40% of all breast cancers.

Source: Advaxis, Inc.

Explore further: World first trial of Tasmanian devil vaccine begins in the wild

Related Stories

DNA-based nanodevices for molecular medicine

September 24, 2015

Researchers from Aalto University have published an article in the recent Trends in Biotechnology journal. The article discusses how DNA molecules can be assembled into tailored and complex nanostructures, and further, how ...

Cancer decoy could attract, capture malignant cells

September 11, 2015

A small, implantable device that researchers are calling a cancer "super-attractor" could eventually give doctors earlier warnings of relapse in breast cancer patients and even slow the disease's spread to other organs.

Team re-engineers virus to deliver therapies to cells

September 21, 2015

Stanford researchers have ripped the guts out of a virus and totally redesigned its core to repurpose its infectious capabilities into a safe vehicle for delivering vaccines and therapies directly where they are needed.

Recommended for you

How the finch changes its tune

August 3, 2015

Like top musicians, songbirds train from a young age to weed out errors and trim variability from their songs, ultimately becoming consistent and reliable performers. But as with human musicians, even the best are not machines. ...

Machine Translates Thoughts into Speech in Real Time

December 21, 2009

( -- By implanting an electrode into the brain of a person with locked-in syndrome, scientists have demonstrated how to wirelessly transmit neural signals to a speech synthesizer. The "thought-to-speech" process ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.